4.4 Review

Wnt Signaling in Liver Cancer

Journal

CURRENT DRUG TARGETS
Volume 9, Issue 11, Pages 1013-1024

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945008786786127

Keywords

-

Funding

  1. National Institutes of Health [CA47207, CA123238]
  2. New York State Department of Health [NYS C021339]
  3. Strang Cancer Prevention Center.

Ask authors/readers for more resources

Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. As in many other types of cancer, aberrant activation of the canonical Wnt/beta-catenin signaling pathway is an important contributor to tumorigenesis. In HCC this frequently occurs through mutations in the N-terminal region of beta-catenin that stabilize the protein and permit an elevated level of constitutive transcriptional activation by beta-catenin/TCF complexes. In this article we review the abundant evidence that Wnt/catenin signaling contributes to liver carcinogenesis. We also discuss what is known about the roles of Wnt signaling in liver development, regeneration, and stem cell behavior, in an effort to understand the mechanisms by which activation of the canonical Wnt pathway promotes tumor formation in this organ. The Wnt/beta-catenin pathway presents itself as an attractive target for developing novel rational therapies for HCC, a disease for which few successful treatment strategies are currently available.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available